Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Radiation Therapy and Overall Survival in Perineural Invasion-Positive Cutaneous Squamous Cell Carcinoma of the Head and Neck: A National Cancer Database Analysis.
Journal: Head & neck
Published: April 23, 2026
Friend, not Foe: Lowered Tissue Reactivity to Long-Term Polyimide Implants.
Journal: bioRxiv : the preprint server for biology
Published: February 23, 2026
Friend, Not Foe: Lowered Tissue Reactivity to Long-Term Polyimide Implants.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: January 14, 2026
Developmental toxicology profile of the IRAK4 degrader KT-474.
Journal: Toxicological sciences : an official journal of the Society of Toxicology
Published: December 12, 2025
Developmental Toxicology Profile of the IRAK4 Degrader KT-474.
Journal: Toxicological sciences : an official journal of the Society of Toxicology
Published: December 12, 2025
Targeted degradation of MK2 is insufficient to block inflammatory cytokine production in human cells due to cooperativity with MK3 and MK5.
Journal: Frontiers in immunology
Published: September 24, 2025
Discovery of Selective and Orally Bioavailable Heterobifunctional Degraders of Cyclin-Dependent Kinase 2.
Journal: Journal of medicinal chemistry
Published: August 20, 2025
Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.
Journal: The Journal of clinical investigation
Published: August 11, 2025
Cefadroxil-Induced Radiation Recall Dermatitis: A Case Report and Review of the Literature.
Journal: Cureus
Published: July 25, 2025
Ultraviolet and infrared radiation in Australia: assessing the benefits, risks, and optimal exposure guidelines.
Journal: Frontiers in public health
Published: October 03, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases.
Journal: Journal of medicinal chemistry
Published: August 16, 2024
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma.
Journal: Journal of medicinal chemistry
Published: June 26, 2024
Last Updated: 09/26/2026